{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:23:17Z","timestamp":1787296997140,"version":"build-2736575974"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1184009"],"award-info":[{"award-number":["GNT1184009"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2012848"],"award-info":[{"award-number":["GNT2012848"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2028506"],"award-info":[{"award-number":["GNT2028506"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Early-stage prostate cancer (PCa) is overwhelmingly driven by aberrant androgen receptor (AR) signalling. Accordingly, standard-of-care treatments include androgen deprivation therapy (ADT) and AR pathway inhibitors (ARPIs), with disease detection and therapy-response monitoring relying on blood-borne PSA, a product of AR transcriptional programs. Crucially, resistance to these therapies is inevitable but heterogeneous in nature; potentially driven by a diverse array of alternate signalling pathways and differentiation mechanisms such as neuroendocrine conversion. Here, we review the current standard of care for CRPC and highlight this heterogeneity - between and even within patients - which demands a new paradigm to longitudinally monitor the evolving molecular profiles of each patient to guide rational selection of targeted therapies, as well as rational patient stratification to optimise clinical trials for emerging therapies. Since solid biopsies are incompatible with extensive longitudinal profiling, we here consider recent advances in liquid biopsy-based profiling methods and assess their potential as cornerstones in a new paradigm of personalised, adaptable disease monitoring and therapeutic decision-support.<\/jats:p>","DOI":"10.3389\/fcell.2026.1894354","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:34:34Z","timestamp":1787294074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development"],"prefix":"10.3389","volume":"14","author":[{"given":"Timothy J.","family":"Mann","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, University of New South Wales","place":["Sydney, NSW, Australia"]},{"name":"Ingham Institute for Applied Medical Research","place":["Liverpool, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M.","family":"Becker","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, University of New South Wales","place":["Sydney, NSW, Australia"]},{"name":"Ingham Institute for Applied Medical Research","place":["Liverpool, NSW, Australia"]},{"name":"School of Medicine, Western Sydney University","place":["Penrith, NSW, Australia"]},{"name":"South Western Sydney Clinical School, University of New South Wales","place":["Liverpool, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Ingham Institute for Applied Medical Research","place":["Liverpool, NSW, Australia"]},{"name":"School of Medicine, Western Sydney University","place":["Penrith, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[{"name":"School of Medicine, Western Sydney University","place":["Penrith, NSW, Australia"]},{"name":"Nepean Clinical School, University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Lock","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, University of New South Wales","place":["Sydney, NSW, Australia"]},{"name":"Ingham Institute for Applied Medical Research","place":["Liverpool, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2300694","DOI":"10.1200\/po.23.00694","article-title":"Androgen receptor splice variant 7 in Asian patients with metastatic castration-resistant prostate cancer","volume":"8","author":"Ang","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1158\/1078-0432.ccr-21-1625","article-title":"Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition","volume":"27","author":"Annala","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and dna mismatch repair gene mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur. Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Communications"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-Deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat. Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-based genomic testing in prostate cancer: 10-Year analysis of national trends on the use of prolaris, decipher, ProMark, and oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin. Practice"},{"key":"B14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40364-024-00680-z","article-title":"Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: unveiling resistance mechanisms with the CoDuCo in situ assay","volume":"12","author":"Bonstingl","year":"2024","journal-title":"Biomark. Res."},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.64898\/2025.12.16.694669","volume-title":"Cytof-based Profiling of Circulating Tumor Cells Predicts Aggressiveness and Therapy Response in SCLC Liquid Biopsies at a Personalized Level","author":"Bose","year":"2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/pros.24400","article-title":"Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration\u2010resistant prostate cancer","volume":"82","author":"Bray","year":"2022","journal-title":"Prostate"},{"key":"B17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"key":"B18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41391-024-00869-1","article-title":"Clinical implications of wnt pathway genetic alterations in men with advanced prostate cancer","volume":"28","author":"Broderick","year":"2025","journal-title":"Prostate Cancer Prostatic Diseases"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13579","DOI":"10.1038\/s41598-019-49964-7","article-title":"Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer","volume":"9","author":"Carm","year":"2019","journal-title":"Sci. Reports"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1158\/1078-0432.ccr-12-2219","article-title":"Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08\/07)","volume":"18","author":"Cathomas","year":"2012","journal-title":"Clin. Cancer Research"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","article-title":"The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Communications"},{"key":"B23","doi-asserted-by":"publisher","first-page":"PO-17","DOI":"10.1200\/PO.17.00169","article-title":"Polyclonal BRCA2 reversion mutations detected in circulating tumor DNA after platinum chemotherapy in a patient with metastatic prostate cancer","volume":"2","author":"Cheng","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur. Journal Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"oyaf107","DOI":"10.1093\/oncolo\/oyaf107","article-title":"Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer","volume":"30","author":"Conteduca","year":"2025","journal-title":"Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.eururo.2014.05.039","article-title":"Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort","volume":"67","author":"Cooperberg","year":"2015","journal-title":"Eur. Urology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence","volume":"23","author":"Coutinho","year":"2016","journal-title":"Endocrine-related Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ccell.2025.07.008","article-title":"Circulating tumor cells: blood-Based detection, molecular biology, and clinical applications","volume":"43","author":"Dai","year":"2025","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(10)61389-x","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/nejmoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/nejmoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","article-title":"Ectopic JAK\u2013STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance","volume":"3","author":"Deng","year":"2022","journal-title":"Nat. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1202277","DOI":"10.3389\/fonc.2023.1202277","article-title":"Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer","volume":"13","author":"Dincman","year":"2024","journal-title":"Front. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Network Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-Deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"34930","DOI":"10.18632\/oncotarget.9004","article-title":"Heterogeneous PSMA expression on circulating tumor cells-a potential basis for stratification and monitoring of PSMA-Directed therapies in prostate cancer","volume":"7","author":"Gorges","year":"2016","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"8145173","DOI":"10.1155\/2022\/8145173","article-title":"Causes of death after prostate cancer diagnosis: a population\u2010based study","volume":"2022","author":"Guo","year":"2022","journal-title":"Oxidative Medicine Cellular Longevity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.64898\/2025.12.30.697072","article-title":"Extracellular matrix regulates lineage plasticity in prostate cancer through YAP\/TEAD","author":"Han","year":"2025","journal-title":"bioRxiv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B55","first-page":"289-e19","article-title":"Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"Hayman","year":"2019"},{"key":"B56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone\u2010specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration\u2010resistant prostate cancer undergoing abiraterone therapy","volume":"119","author":"Heck","year":"2017","journal-title":"BJU International"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nat. Communications"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B59","author":"Howlader","year":"2021"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/nejmoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/jpm12010065","article-title":"Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer","volume":"12","author":"Ingrosso","year":"2022","journal-title":"J. Personalized Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/onc.2014.238","article-title":"DNA damage response and prostate cancer: defects, regulation and therapeutic implications","volume":"34","author":"Karanika","year":"2015","journal-title":"Oncogene"},{"key":"B69","doi-asserted-by":"publisher","first-page":"868031","DOI":"10.3389\/fonc.2022.868031","article-title":"Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Khan","year":"2022","journal-title":"Front. Oncology"},{"key":"B70","first-page":"S273","article-title":"Management of biochemically recurrent prostate cancer following local therapy","volume":"20","author":"Kolodziej","year":"2014","journal-title":"Am. J. Manag. Care"},{"key":"B71","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: from a \u201ccold\u201d tumor to a \u201chot\u201d prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.3390\/cancers15205047","article-title":"Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers"},{"key":"B75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discovery"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3892\/ol.2017.6332","article-title":"Circulating tumor cells in prostate cancer: precision diagnosis and therapy","volume":"14","author":"Liu","year":"2017","journal-title":"Oncol. Letters"},{"key":"B77","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41419-025-08280-x","article-title":"Targeting secreted PLA2 interactions with EGFR and vimentin to arrest prostate tumour growth","volume":"17","author":"Mann","year":"2025","journal-title":"Cell Death and Dis."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.23.684075","article-title":"Deep multiplexed 50-marker imaging of circulating tumor cells expands actionable biomarker profiling for precision oncology","author":"Mann","year":"2025","journal-title":"bioRxiv"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J. Clinical Investigation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1185\/03007995.2014.919908","article-title":"Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study","volume":"30","author":"Michalopoulos","year":"2014","journal-title":"Curr. Medical Research Opinion"},{"key":"B82","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41467-024-55140-x","article-title":"Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product","volume":"16","author":"Mishra","year":"2025","journal-title":"Nat. Communications"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","article-title":"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer","volume":"16","author":"Mizuno","year":"2025","journal-title":"Nat. Commun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.euf.2021.03.015","article-title":"Association between oncotype DX genomic prostate score and adverse tumor pathology after radical prostatectomy","volume":"8","author":"Moschovas","year":"2022","journal-title":"Eur. Urology Focus"},{"key":"B85","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cells8070688","article-title":"Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes","volume":"8","author":"Nimir","year":"2019","journal-title":"Cells"},{"key":"B87","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1754-9485.13658","article-title":"Current state of theranostics in metastatic castrate\u2010resistant prostate cancer","volume":"68","author":"Nindra","year":"2024","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"B88","first-page":"38-e17","article-title":"Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature","volume-title":"Urologic Oncology: Seminars and Original Investigations","author":"Nishiyama","year":"2014"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.21037\/tau-20-1118","article-title":"Current treatment options for newly diagnosed metastatic hormone-sensitive prostate Cancer\u2014A narrative review","volume":"10","author":"Ong","year":"2021","journal-title":"Transl. Androl. Urology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","article-title":"Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium","volume":"17","author":"Paller","year":"2019","journal-title":"Clin. Genitourinary Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"17588359231220506","DOI":"10.1177\/17588359231220506","article-title":"Nomogram to predict the presence of PSMA-Negative but FDG-Positive lesion in castration-resistant prostate cancer: a multicenter cohort study","volume":"16","author":"Pan","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a PROteolysis TArgeting chimera (PROTAC) androgen receptor degrader, in metastatic castration-resistant prostate cancer: initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B97","first-page":"3","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume-title":"Seminars in Oncology","author":"Pienta","year":"2001"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Communications"},{"key":"B100","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","volume":"5","author":"Romero","year":"2024","journal-title":"Nat. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/pcan.2013.49","article-title":"A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy","volume":"17","author":"Ross","year":"2014","journal-title":"Prostate Cancer Prostatic Diseases"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"71","author":"Scher","year":"2017","journal-title":"Eur. Urology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Diseases"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. Journal Molecular Sciences"},{"key":"B111","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"key":"B113","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41391-022-00491-z","article-title":"Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids","volume":"26","author":"Snaterse","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-031-22903-9_1","article-title":"CTC-based liquid biopsies and diagnostic leukapheresis","volume-title":"Circulating Tumor Cells: Advances in Liquid Biopsy Technologies","author":"Stoecklein","year":"2023"},{"key":"B115","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41391-020-00308-x","article-title":"Clinical implications of genomic alterations in metastatic prostate cancer","volume":"24","author":"Sumiyoshi","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B116","first-page":"385","article-title":"Debate 1: radical prostatectomy for the right patient with high-risk prostate cancer","volume-title":"Seminars in Radiation Oncology","author":"Sundaresan","year":"2025"},{"key":"B117","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/nejmoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"B121","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J. Cancer Research Clinical Oncology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev-pathol-052016-100256","article-title":"Circulating tumor cells: fluid surrogates of solid tumors","volume":"12","author":"Thiele","year":"2017","journal-title":"Annu. Rev. Pathology Mech. Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.bjc.6605376","article-title":"Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth","volume":"101","author":"Traish","year":"2009","journal-title":"Br. Journal Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/cam4.594","article-title":"Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases","volume":"5","author":"Varenhorst","year":"2016","journal-title":"Cancer Medicine"},{"key":"B126","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1038\/s41598-024-57381-8","article-title":"Ultra high content analyses of circulating and tumor associated hybrid cells reveal phenotypic heterogeneity","volume":"14","author":"Whalen","year":"2024","journal-title":"Sci. Rep."},{"key":"B128","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15252\/emmm.201303701","article-title":"Targeting the adaptive molecular landscape of castration\u2010resistant prostate cancer","volume":"7","author":"Wyatt","year":"2015","journal-title":"EMBO Molecular Medicine"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e257089","DOI":"10.6004\/jnccn.2025.7089","article-title":"A prospective validation of the decipher genomic classifier in men with early localized prostate cancer: the VANDAAM study","volume":"24","author":"Yamoah","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1894354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:34:37Z","timestamp":1787294077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1894354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":107,"alternative-id":["10.3389\/fcell.2026.1894354"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1894354","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1894354"}}